Latest Breaking News On - Jessica serra - Page 3 : comparemela.com

Revance Therapeutics (RVNC) Provides an Update on DAXXIFY Launch, Reports Prelim Q4 Results

Revance Therapeutics (RVNC) Provides an Update on DAXXIFY Launch, Reports Prelim Q4 Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSaraj fahyMarkj foleyLaurence wattsJessica serraDustins sjutsAllergan incRevance therapeutics incHint incService revenueDrug administrationPeptide exchange technologyEvolus incExchange commissionIpsen biopharmaceuticals ltdGilmartin group

Revance Announces U S FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Revance Announces U S FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMarkj foleyLaurence wattsJessica serraSara fahyPeter mcallisterAllergan incRevance therapeutics incHint incDystonia medical research foundationDrug administrationPeptide exchange technologyEvolus incExchange commissionGilmartin groupIpsen biopharmaceuticals ltd

Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference

Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMarkj foleyJessica serraLaurence wattsSara fahyAllergan incGilmartin groupRevance therapeutics incViatris incAnnual piper sandler healthcare conferenceChief executive officerInvestor relationsRelational commerceRevance therapeuticsHyaluronic acid

Revance Therapeutics, Inc (RVNC) Q3 2022 Earnings Call Transcript

Revance Therapeutics, Inc. (NASDAQ:NASDAQ:RVNC) Q3 2022 Results Conference Call November 08, 2022 04:30 PM ET Company Participants Jessica Serra - Head of Investor Relations & ESG Mark.

United statesSan diegoTobin schilkePiper sandlerFosun pharmaChris shibutaniJessica serraJustin phillipsRohit bhasinBalaji prasadDavid amsellemTerence flynnStacy leeToby schilkeDustin sjutsMark foley

Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update

Received FDA approval for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar linesQ3 total revenue of $29.0 million, a YoY increase of 47% with RHA® Collection revenue of $26.1 million, a YoY increase of 43%Aesthetic accounts across products and services totaled over 4,500 at quarter-en.

United statesMarkj foleyDavid hollanderLaurence wattsJessica serraAllergan incAjinomoto biopharma servicesRevance therapeutics incHint incDrug administrationPeptide exchange technologyEvolus incAjinomoto biopharma services ajiExchange commissionIpsen biopharmaceuticals ltdGilmartin group